Loading...
Market
Will Takeda announce a new Huntington's disease collaboration by June 30, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Takeda Pharmaceutical Company
Story
Takeda Ends Six-Year $260M Collaboration with Wave Life Sciences on Mutant Huntingtin-Specific ASO
Oct 16, 2024, 08:55 AM
Takeda Pharmaceutical Company, a Japanese pharma, has decided to terminate its option for the mutant huntingtin-specific ASO target in its collaboration with Wave Life Sciences. This decision marks the end of a six-year partnership into which Takeda had invested $260 million. The collaboration was focused on developing treatments for Huntington's disease.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
